- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00285454
Cell Repair in Heart Failure
A Phase I/II, Randomised, Double-blind, Placebo Controlled, Single-centre Study of Bone Marrow Mononuclear Cells by Percutaneous Retrograde Coronary Venous Delivery to Patients With Ischaemic Heart Failure and no Standard Revascularisation Options.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Study Objectives:
- Evaluate the safety of a single administration of bone marrow mononuclear cells by retrograde coronary venous delivery.
- Evaluate the bioactivity of bone marrow mononuclear cells in mediating increased perfusion in viable underperfused areas of myocardium.
- Evaluate the ability of bone marrow mononuclear cells to improve myocardial function specifically regional wall motion and cardiac synchronisation.
- Evaluate the use of potential bioactivity assays and clinical outcomes for assessing bone marrow mononuclear cell- induced myocardial changes.
Study Design:
A phase I/II, randomised, double-blind, placebo controlled, single-centre study of bone marrow mononuclear cells by percutaneous retrograde coronary venous delivery to patients with ischaemic heart failure and no standard revascularisation options.
Study Population:
Patients with symptomatic ischaemic heart failure, not amenable to conventional revascularisation strategies (PCI, CABG, LVAD) or transplantation.
Independent Eligibility:
The results of the screening procedures will be compiled and submitted to an independent interventional cardiologist and cardiac surgeon who are not associated with the study for consideration for enrolment. It will be the independent reviewer's responsibility to confirm eligibility prior to a patient participating in the study.
Product:
Autologous bone marrow mononuclear, the first 6 safety and feasibility patients (open-labelled) will receive a sub-population of Indium-111 labelled cells to assess feasibility of delivery. The remaining patients will either receive Active: Bone marrow mononuclear cells and 5 % HSA Placebo: 5% HSA
Route:
Retrograde coronary venous delivery The total dose of bone marrow mononuclear cells or placebo will be divided into two, each administered as a 10ml bolus into a selective coronary veins. There will be significant patient heterogeneity regarding size of ischaemic viable territory present and anatomy of venous system. We aim to treat two veins, individual SPECT and venogram results will be used to direct the venous anatomy to be targeted. An attempt will be made to cover as large an area as possible of a patient's ischaemic viable territory. The total dose of cells will remain constant between patients.
Safety:
The first 6 patients will receive cells as an adjunct to Cardiac resynchronization Therapy and ICD. An external Data Safety and Monitoring Board has also been appointed to oversee this study.
Studietype
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Middlesex
-
London, Middlesex, Storbritannia, SW3 6LR
- The Department of Gene Therapy, The National Heart and Lung Institute, Imperial College London and The Royal Brompton Hospital.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Symptomatic ischaemic multi-vessel coronary artery disease (CAD) not suitable for standard revascularization procedures such as CABG, PCI, LVAD, or heart transplant.
- Area of reversible inducible ischaemia (>10% of LV on SPECT) performed not more than six months prior to study treatment.
- LVEF < 45% on optimal medical therapy.
- NYHA class II- IV patient stable on optimal medical therapy for at least 30 days.
- Written informed consent and agree to attend hospital appointments for 1 year.
- Male and females 18 to 80 years of age.
Exclusion Criteria:
- Left ventricular aneurysm or thrombus.
- Thoracic aortic aneurysm.
- Congenital Heart disease
- Acute unstable angina, idiopathic cardiomyopathy, life-threatening ventricular arrhythmias, recent (less than 6 weeks).
- Contraindication to MRI or any other study procedure.
- Presence or history of cancer (except low grade and fully resolved non-melanoma skin malignancy).
- Any co-morbidity likely to reduce short- term survival or which may interfere with functional testing.
- Recent myocardial infarction < 6mths.
- Cerebral vascular accident < 6mths.
- Active hepatitis, receiving immunosuppressive therapy, undergoing haemodialysis.
- Clinically significant abnormal haematology.
- Recent history of alcoholism, drug abuse, or severe emotional, behavioural, or psychiatric problems.
- Fertile women who are pregnant, nursing, or using no form of contraception.
- Receiving experimental medications or participating in another study within 12 weeks of enrolment into this study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Hva måler studien?
Primære resultatmål
Resultatmål |
---|
Effektivitet
|
Safety: up to one year
|
Co-primary endpoints at 180 Days
|
Perfusion (MIBI SPECT)
|
Function (CMR)
|
Sekundære resultatmål
Resultatmål |
---|
QOL
|
Efficacy: at 180 days
|
Perfusion (CMR)
|
Function (ECHO, SPECT)
|
Exercise (VO2 Max)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Eric WF Alton, The Department of Gene Therapy, The NHLI Imperial College London
- Hovedetterforsker: Jonathan R Clague, The Royal Brompton Hospital London
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Amanda Heinl-Green
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Iskemi
-
Groupe Hospitalier Paris Saint JosephFullført
-
University Hospital, AntwerpRekrutteringBrystrekonstruksjon | Mastektomi | Flap IschemiBelgia
-
Queen Mary University of LondonUniversity College, LondonTilbaketrukketIschemi-reperfusjon (IR) skadeStorbritannia
-
Ruhr University of BochumUkjentKomplikasjon av kirurgisk prosedyre | Flap IschemiTyskland
-
Assiut UniversityUkjent
-
Meshalkin Research Institute of Pathology of CirculationFullførtKronisk lemmer-truende ischemiDen russiske føderasjonen
-
National Heart, Lung, and Blood Institute (NHLBI)FullførtIskemisk forkondisjonering | Ischemi i lemmerForente stater
-
Center of New Medical TechnologiesHar ikke rekruttert ennåIschemi i lemmerDen russiske føderasjonen
-
R3 Vascular Inc.RekrutteringKritisk iskemi i lemmer | Kritisk iskemi i nedre ekstremiteter | Kritisk lemmer-truende ischemiAustralia
-
Seoul National University HospitalFullførtBlodstrøm | Klappnekrose | Flap Ischemi | Anastomotisk svikt i klaffKorea, Republikken